XenoPort to Present at the 2015 Wells Fargo Healthcare Conference
September 02 2015 - 10:30AM
Business Wire
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will
provide access via the World Wide Web to its presentation at the
2015 Wells Fargo Healthcare Conference. The live presentation will
occur at 10:10 a.m. Pacific Time (1:10 p.m. Eastern Time) on
Wednesday, September 9, 2015. A replay of the presentation will
also be available.
To access the live presentation via the Web, please go to
www.XenoPort.com. Please connect to the Web site at least 15
minutes prior to the live presentation to ensure adequate time for
any software downloads that may be necessary to listen to the
Webcast.
A replay of the Webcast can be accessed for a minimum of one
month and will be available approximately 24 hours after the live
presentation.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on
developing and commercializing a portfolio of internally discovered
product candidates for the potential treatment of neurological
disorders. XenoPort is currently commercializing HORIZANT®
(gabapentin enacarbil) Extended-Release Tablets in the United
States and developing its novel fumaric acid ester product
candidate, XP23829, as a potential treatment for patients with
moderate-to-severe chronic plaque-type psoriasis and potentially
for relapsing forms of multiple sclerosis. REGNITE® (gabapentin
enacarbil) Extended-Release Tablets is being marketed in Japan by
Astellas Pharma Inc. XenoPort has entered into a clinical trial
agreement with the National Institute on Alcohol Abuse and
Alcoholism (NIAAA) under which the NIAAA has initiated a clinical
trial evaluating gabapentin enacarbil as a potential treatment for
alcohol use disorder, and XenoPort has granted exclusive world-wide
rights for the development and commercialization of its
clinical-stage oral product candidate, arbaclofen placarbil, to
Indivior PLC for all indications. XenoPort's pipeline of product
candidates also includes a potential treatment for patients with
idiopathic Parkinson's disease.
To learn more about XenoPort, please visit the website at
www.XenoPort.com.
XNPT2G
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150902005408/en/
XenoPort, Inc.Jackie Cossmon, 408-616-7220ir@XenoPort.com
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Apr 2023 to Apr 2024